US 12,263,174 B2
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
Jeffry Weers, Half Moon Bay, CA (US); Alain Romero, Brisbane, CA (US); Hugh Smyth, West Lake Hills, TX (US); Robert Curtis, Santa Fe, NM (US); Adaani Frost, Houston, TX (US); Zhen Xu, Rockville, MD (US); Revati Shreeniwas, Palo Alto, CA (US); and Martin Donovan, Austin, TX (US)
Assigned to Respira Therapeutics, Inc., Palo Alto, CA (US)
Filed by Respira Therapeutics, Inc., Palo Alto, CA (US)
Filed on Jun. 29, 2022, as Appl. No. 17/853,005.
Application 17/853,005 is a continuation of application No. 17/534,282, filed on Nov. 23, 2021, granted, now 11,491,161.
Application 17/534,282 is a continuation of application No. 17/146,173, filed on Jan. 11, 2021, granted, now 11,491,160.
Application 17/146,173 is a continuation of application No. 16/469,524, granted, now 10,912,778, issued on Feb. 9, 2021, previously published as PCT/US2017/066519, filed on Dec. 14, 2017.
Claims priority of provisional application 62/434,185, filed on Dec. 14, 2016.
Prior Publication US 2022/0347183 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/53 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 31/192 (2006.01); A61K 31/506 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/53 (2013.01) [A61K 9/0075 (2013.01); A61K 9/008 (2013.01); A61K 9/1623 (2013.01); A61K 31/192 (2013.01); A61K 31/506 (2013.01); A61P 9/12 (2018.01)] 19 Claims
 
1. A method of treating pulmonary arterial hypertension, comprising administering to the subject in need thereof a therapeutically effective amount of a PDE5 inhibitor by oral inhalation;
wherein the therapeutically effective amount of the PDE5 inhibitor is delivered by a portable inhaler pro re nata.